Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 2

2(28.6%)

Phase 3

1(14.3%)

7Total

Phase 1(4)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04111978Phase 3Recruiting

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

Role: collaborator

NCT02517918Phase 1Completed

Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma

Role: collaborator

NCT02770378Phase 1Completed

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

Role: collaborator

NCT01210378Phase 2Terminated

Nitroglycerin in Non-small Cell Lung Cancer

Role: collaborator

NCT01198821Phase 1Completed

Gem-TABS in Unresectable Pancreatic Carcinoma

Role: collaborator

NCT02017353Phase 2Completed

Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma

Role: collaborator

NCT01846429Phase 1Terminated

Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain

Role: collaborator

All 7 trials loaded